Barclays analyst Gena Wang raised the firm’s price target on Cytokinetics (CYTK) to $71 from $53 and keeps an Overweight rating on the shares. The firm says it has more conviction for aficamten’s opportunity and further differentiation from mavacamten following this weekend’s data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Reveals Promising MAPLE-HCM Trial Results
- Kraft Heinz announces separation, Elliott builds $4B PepsiCo stake: Morning Buzz
- Cytokinetics rises 34.5%
- Promising Phase 3 Trial Results Bolster Buy Rating for Cytokinetics’ Aficamten
- H.C. Wainwright sees ‘little room left for doubt’ on Cytokinetics’ aficamten